ILiAD Biotechnologies, LLC is focused on developing innovative vaccine technologies, particularly targeting pertussis (whooping cough) through their lead candidate, BPZE1. This live attenuated intranasal vaccine has shown promising results in clinical studies, demonstrating excellent safety and immunogenicity profiles. In multiple Phase 1 and Phase 2 trials involving over 360 healthy adults, BPZE1 was well-tolerated, with no serious adverse events reported. The vaccine has been effective in inducing broad mucosal immunity and systemic antibody responses, with significant protection against colonization by Bordetella pertussis, the bacterium responsible for pertussis. The studies indicate that BPZE1 not only provides immediate immune responses but also maintains durability for up to nine months post-vaccination.

In addition to its primary focus on pertussis, ILiAD is exploring the potential of BPZE1 and its B-Tech platform in addressing other health challenges, including allergic diseases and neurodegenerative conditions like Alzheimer’s disease. Preclinical studies have suggested that BPZE1 may protect against allergic airway inflammation and improve key asthma markers. Furthermore, the B-Tech platform is being investigated for its ability to develop a universal influenza vaccine, leveraging BPZE1's mechanism to mitigate the cytokine storm associated with influenza infections. Overall, ILiAD is committed to advancing its vaccine candidates through rigorous clinical development to provide effective solutions for infectious and allergic diseases.

United States

ILiAD Biotechnologies is utilizing its B-Tech vector platform to develop next generation vaccines to eradicate infectious diseases and improve lives. Its lead candidate, BPZE1, which has completed Phase 2 clinical trials, is the most advanced next generation vaccine for the prevention of whooping cough, a serious illness caused by Bordetella pertussis.

ILiAD Biotechnologies, LLC

Company Details